Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable suspending, solubilizing, wetting, emulsifying or lubricating agent
Patent 5492688 Issued on February 20, 1996. Estimated Expiration Date: 
March 23, 2014. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
March 23, 2014. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesAerosol propellant compositions Foaming system for rigid urethane and isocyanurate foams Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content Formulations for delivery of beclomethasone diproprionate by metered dose inhalers containing no chlorofluorocarbon propellants Patent #: 5202110 InventorsAssigneeApplicationNo. 217012 filed on 03/23/1994US Classes:424/45, Organic pressurized fluid424/46, Powder or dust containing424/489, Particulate form (e.g., powders, granules, beads, microcapsules, and pellets)514/958FOR SMOKING OR INHALINGExaminersPrimary: Page, Thurman K.Assistant: Bawa, Raj Attorney, Agent or FirmForeign Patent References
International ClassA61K 009/12AbstractMetered dose inhaler (MDI) formulations which utilize 1,1,1,2-tetrafluoroethane (HFC 134a) as the sole propellant are made practical by including a polar surfactant such as polyethylene glycol, diethylene glycol monoethyl ether, polyoxyethylene (20) sorbitan monolaurate, polyoxyethylene (20) sorbitan monooleate, propoxylated polyethylene glycol, and polyoxyethylene (4) lauryl ether for suspending, solubilizing, wetting and emulsifying the drug constituent and lubricating the valve components of the MDI. | |
